There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...

Please provide your email address to receive an email when new articles are posted on . When divided into five age groups, higher proportions of patients fell in the older vs. younger groupings.

Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced positive Phase 2a ...

Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...